Immunovant Inc. Company Profile
NASDAQ: IMVTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 32.04 0.00%
Immunovant at a glance
Immunovant Inc. (NASDAQ: IMVT) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Durham, NC. Immunovant is led by Dr. Eric Venker M.D., Pharm.D. and employs about 315 people. The company's shares have traded publicly since 2019.
At a market capitalization of $6.63 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001764013, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Immunovant do?
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Business description based on the company's public filings.
Company information
- Legal name
- Immunovant Inc.
- Ticker
- NASDAQ: IMVT
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Eric Venker M.D., Pharm.D.
- Employees
- 315
- Headquarters
- 1000 Park Forty Plaza, Durham, NC, United States
- Phone
- 917 410 3120
- Website
- immunovant.com
- IPO year
- 2019
- Market cap
- $6.63B
- SEC CIK
- 0001764013
- Latest annual report
- 10-K · May 20, 2026
Companies similar to Immunovant
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IOVAIovance Biotherapeutics Inc. | 12.92 | -0.35% | $5.85B | vs IMVT |
| KODKodiak Sciences Inc | 91.08 | -1.36% | $5.72B | vs IMVT |
| CGONCG Oncology Inc. | 62.38 | -1.98% | $5.53B | vs IMVT |
| SRRKScholar Rock Holding Corporation | 42.20 | -0.59% | $5.14B | vs IMVT |
| CRSPCRISPR Therapeutics AG | 52.35 | -3.06% | $5.06B | vs IMVT |
| KYMRKymera Therapeutics Inc. | 108.35 | +2.24% | $8.91B | vs IMVT |
| ADPTAdaptive Biotechnologies Corporation | 26.28 | -2.30% | $4.19B | vs IMVT |
| QGENQiagen N.V. | 44.79 | -1.88% | $9.25B | vs IMVT |